Our promising results of rAd.sT.GM in TNBC also suggest potential applications in other cancers characterized by aberrant TGF-β signaling and/or suppressive immune microenvironment, such as colon cancer,48 ovarian cancer,49 and glioblastoma.50 Here, TGFB1 is linked to ovarian cancer.